June 14, 2023
Ilya Pharma
Ilya Pharma, a clinical stage biopharmaceutical development company is currently pursuing three clinical programs with fully owned assets from its proprietary ILP-technology platform. The formal INN name for the lead asset is emilimogene sigulactibac, the working names are ILP100-Topical and ILP100-Oral and these are classified as ATMP and gene therapies by the EMA and FDA.
Ilya Pharma 是一家处于临床阶段的生物制药开发公司，目前正在利用其专有的 ILP 技术平台的全资资产开展三个临床项目。主要资产的正式INN名称是emilimogene sigulactibac，工作名称是 ILP100-Topical 和 ILP100-Oral，这些被 EMA 和 FDA 归类为 ATMP 和基因疗法。
Atriva Therapeutics
Atriva Therapeutics is a biopharmaceutical company pioneering the development of first-in-class host-cell-targeting antiviral and immunomodulatory therapies. The company was set up by a team of leading scientists in viral disease research and industry experts with a proven track record. Atriva aims to develop novel, highly efficacious and safe therapies for the treatment of severe diseases caused by RNA-viruses with a high unmet medical need and huge cost burden to healthcare systems around the world such as influenza virus, respiratory syncytial virus infections, dengue fever and hanta virus infections. Atriva’s lead product zapnometinib (previously known as ATR-002) is a novel, first-in-class host-cell-targeting, orally available small molecule drug inhibiting viral replication and rebalancing the body’s immune response.
Atriva Therapeutics是一家生物制药公司，致力于开发首创的针对宿主细胞的抗病毒和免疫调节疗法。该公司由一支由病毒疾病研究的领先科学家和在行业中具有成功记录的专家团队组成。Atriva旨在开发新颖、高效安全的治疗方案，用于治疗由RNA病毒引起的严重疾病，这些疾病在全球范围内对医疗系统造成巨大的负担，且目前医学需求未得到满足，包括流感病毒、呼吸道合胞病毒感染、登革热和汉他病毒感染等。Atriva的主力产品zapnometinib（之前称为ATR-002）是一种新颖的、首创的靶向宿主细胞的口服小分子药物，能够抑制病毒复制并重新平衡人体的免疫应答。
Bilayer Therapeutics
Bilayer Therapeutics seeks to develop bile acids as first-in-class therapies to treat diseases of the colon using a GLP-1 based mechanism of action and a unique and proprietary colonic delivery technology. First in its portfolio is BL-010, a therapy for chronic constipation as beachhead indication followed by BL-050, an orally available therapy for metabolic disorders such as obesity and diabetes which acts through increasing native levels of GLP-1.
Bilayer Therapeutics致力于利用基于GLP-1机制的胆汁酸及独特专利的结肠递送技术，将其作为首创疗法开发，用于治疗结肠疾病。其产品组合中首个项目是BL-010，首个适应症用于治疗慢性便秘； BL-050是一款口服药物，增加GLP-1 的天然水平治疗代谢性疾病，如肥胖症和糖尿病。
Regeneus
Regeneus is a paradigm shift in cellular-based therapy for regenerative medicine. Their platform technologies Progenza™ and Sygenus are novel approaches to pain, that leverage stem cells as cellular pharmacies and utilise Secretome as a therapeutic agent. Regeneus’ product pipeline consists of two platform technologies, Progenza™ and Sygenus, across three target therapeutic areas: osteoarthritis, neuropathic pain and skin wound healing.
Regeneus是再生医学领域中细胞治疗的一个范式转变。他们的平台技术Progenza™和Sygenus是针对疼痛的新颖方法，利用干细胞的分泌物作为治疗药物。Regeneus 的产品线包括两个平台技术，Progenza ™和 Sygenus，跨越三个目标治疗领域：骨关节炎、神经性疼痛和皮肤伤口愈合。
Lumos Pharma
Lumos Pharma is a clinical-stage biopharmaceutical company whose mission is to develop new therapies for people with rare diseases, prioritizing its focus where the medical need is high, and the pathophysiology is clear. They are committed to this mission and a strategy that is grounded upon time and cost-efficient drug development to deliver safe and effective therapies to patients. Also known as ibutamoren, LUM-201 is an orally administered small molecule that promotes the secretion (secretagogue) of Growth Hormone (GH) from the pituitary gland.1
Lumos Pharma是一家临床阶段的生物制药公司，其使命是为罕见疾病患者开发新的治疗方法，优先关注医疗需求高、病理生理学清晰的领域。致力于这一使命，公司采取了基于时间和成本效益的药物开发策略，以向患者提供安全有效的治疗方案。LUM-201，也被称为ibutamoren，是一种口服小分子药物，可以促进垂体腺分泌生长激素（GH）的分泌（促分泌剂）。
HysensBio
HysensBio developed a new medicine for cavity and dentin hypersensitivity to overcome the limitations of dental treatment and to provide high-quality of dental cares solution to patients. They constantly challenge ourselves to go beyond our imagination, create the value for customers with their passion, and to become the global market leader in dental and medical industries.
HysensBio开发了一种新的治疗腔内和牙本质敏感的药物，以克服牙科治疗的局限性，并为患者提供高质量的牙科护理解决方案。他们不断挑战自己，超越想象，用他们的激情为客户创造价值，并成为牙科和医疗行业的全球市场领导者。
Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc is a late clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for people with rare tumors and aggressive cancers. Its asset, AL102, is an investigational, once-daily oral small molecule inhibitor of gamma secretase in Phase 3 development for the treatment of desmoid tumors (DT). Their global registration-enabled Phase 3 study, RINGSIDE, is ongoing and registrations are going well in the US, EU, Australia, South Korea and Israel. The program has received Fast Track designation from the FDA. Clinical data from the open-label Phase 2 study increases the likelihood of a successful outcome for this registrational trial and reveals differences from SpringWorks’ nirogacestat, another investigational drug in the same class.
Ayala Pharmaceuticals, Inc 是一家后期临床阶段的肿瘤学公司，专注于为患有罕见肿瘤和侵袭性癌症的人开发和商业化小分子疗法。其资产AL102 是一种在研的、每日一次的口服的γ分泌酶小分子抑制剂，处于临床3 期阶段，用于治疗硬纤维瘤 (DT)的 RINGSIDE试验正在进行中，在美国、欧盟、澳大利亚、韩国和以色列开展。 该产品已获得 FDA 的快速通道认证。 2 期数据增加了试验成功的可能性，并展示了与 SpringWorks 的 nirogacestat（同一类别的另一种研究药物）的区别。
Introduction to Japan MedTech Market – Hekabio
Medtech ETF Analysis and M&A and IPO Transactions – BioConnexus
Cardiospire
Cardiospire is a developer of a portable device designed to monitor cardiac health. The company’s portable device offers proprietary insights into the pulmonary vasculature non-invasively and aims to address both at-home monitoring and critical care applications in categories such as heart failure and hemodynamics, enabling medical professionals to help patients obtain reproducible measurements independent of interpatient variability with little to no subject training required.
Cardiospire 旨在开发监测心脏健康的便携式设备。该公司的便携式设备以非侵入方式提供对肺血管系统的评估，用于心力衰竭和血液动力学等类别的家庭监测和重症监护，使医疗专业人员能够帮助患者获得独立于患者间可变性的可重复测量结果，几乎不需要受试者培训。
ArcScan
ArcScan, a dynamic and innovative company established in February 2007 in Golden, Colorado, aims to advance and advance medical imaging globally using intelligent UHF ultrasound technology to improve diagnostic and surgical outcomes. The ArcScan Insight® 100 instrument is a unique resource for imaging that highlights areas of the eye in micron-level detail. With the images you capture, you can visualize and measure anatomy that adds critical insight for pre- and post-surgical assessment as well as treatment decision making.
ArcScan，于 2007 年 2 月在科罗拉多州戈尔登成立，旨在通过使用智能超高频超声技术在全球范围内推进和发展医学成像，从而改善诊断和手术结果。ArcScan Insight® 100 成像技术提供极高的准确性，可以在整个眼睛前房中进行测量。该设备和软件平台能使用户能以微米精度轻松获得整个眼球前部的超高分辨率图像，包括当前光学技术无法成像的区域。Swept BeamLiquid Interface™ 技术在超声成像方面取得了巨大的发展，其精度无与伦比。
Venock Inc.
Venock Inc. is a privately held US medical device company headquartered in New York City, with a subsidiary Venock Medical GmbH in Munich. Its Vascular Closure Device is designed to close very large perforations that can be as big as the diameter of the operable vein or artery.
Venock Inc. 是一家美国医疗器械私营公司，总部位于纽约市，在慕尼黑设有子公司 Venock Medical GmbH。其血管闭合装置旨在闭合非常大的穿刺孔，这些穿刺孔可以与可手术静脉或动脉的直径一样大。
Artract
Artract is a developer of hemodynamic assist devices used to treat the heart diseases. The company provides a percutaneously implanted passive hemodynamic assist device for the treatment of heart failure with preserved ejection fraction that reduces left atrial blood pressure, relieves shortness of breath, increases cardiac chamber filling, and does not require an energy source or motor, enabling patients to improve their quality of life.
Artract是一家用于心脏疾病治疗的血液动力学辅助设备的开发商。 该公司提供一种经皮植入的被动血流动力学辅助装置，用于治疗射血分数保留的心力衰竭，可降低左心房血压，缓解呼吸急促，增加心腔充盈，并且不需要电源或电机，使患者能够提高他们的生活质量。
Renexxion
Renexxion is a private Irish biopharmaceutical company developing innovative medicines for gastrointestinal diseases. In 2022, the company received an investment commitment of 630 million yuan from GEM Group. Its asset is a novel small-molecule pan-GI prokinetic agent, which has achieved positive results in 4 Phase 2 clinical trials in upper and lower GI tract indications with 972 subjects, proving its safety and efficacy and the IND has been submitted in China. Renexxion has established a product development and commercialization partnership with Dr. Falk, a well-known European gastrointestinal company, and is conducting phase 2 clinical trials for gastroparesis in Europe.
Renexxion是一家爱尔兰私营生物制药公司，致力于开发胃肠道疾病创新药物。公司在 2022 年获得GEM 集团 6.3 亿元投资承诺。其资产是一种新型小分子泛胃肠道促动力药，已在上、下胃肠道适应症的 4个2 期临床、972 名受试者中取得积极结果，证明了其安全性和有效性。标的资产在国内已经递交 IND 电请。已与欧洲知名胃肠道公司 Dr. Falk 建立产品开发及商业化合作关系，正在欧洲开展胃轻瘫 2 期临床试验。
Contact us
Wendi Xiang
BioToChina.org 